ClinicalTrials.gg
CompletedNCT03509415Updated Apr 16, 2024

Reflectance Confocal Microscopy to Diagnose BCC

An observational study in Basal Cell Carcinoma, sponsored by Skin Care Network Ltd.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Skin Care Network Ltd. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
324
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 29 studies in Carcinoma, Basal Cell with a site in United Kingdom — none open to participants now, none under way, none of them phase 3. Carcinoma, Basal Cell · United Kingdom.

Started
2017
with 3 others
Observational
5 of 29
none open now
Registered
21st of 29
by date

Among the 29 studies in Carcinoma, Basal Cell with a site in United Kingdom, this one is one of 4 that started in 2017, is one of 5 observational ones, and was the 21st registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

None of the 29 studies in Carcinoma, Basal Cell with a site in United Kingdom is open now. The open studies under Carcinoma, Basal Cell, anywhere →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Carcinoma, Basal Cell with a site in United Kingdom as a file.
02

Study summary

It is proposed to undertake a study to determine the diagnostic utility of using RCM for the diagnosis of Basal Cell Carcinoma (BCC) in a tertiary referral centre as outlined by the recent NICE report (Nov 2015). This will allow an assessment of the potential to avoid diagnostic biopsy within the treatment pathway.

Read the detailed description

Study Design This is an observational, non-randomised, non-controlled, prospective cohort study to look at the efficacy of in vivo RCM as a diagnostic tool in the diagnosis of BCC.

Study Hypothesis The hypothesis of this study is that the use of RCM is would enable a reduction in the number of diagnostic biopsies taken before definitive treatment of BCC by at least 50%.

The secondary hypothesis is that the intra- \& inter-observer agreement for interpreting the RCM images will have kappa scores 0.6 or greater (indicating good agreement).

Patients will be recruited from the outpatient clinic of Skin Care Network London.

03

Conditions studied

  • Basal Cell Carcinoma

Keywords

  • Confocal
  • RCM
  • Imaging
  • Skin cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients presenting at a skin cancer clinic with a lesion that is clinically suspicious for BCC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older
  2. Patient suspected of having a primary basal cell carcinoma that is a candidate for surgical treatment.
  3. Patient willing and able to give

Exclusion criteria

Exclusion Criteria:

  1. Recurrent or other higher-risk BCC
  2. Patient with basal cell naevus syndrome
  3. Patient treated with hedgehog inhibitor medication (vismodegib)
  4. Patient not suitable for diagnostic
  5. Location of lesion unsuitable, inaccessible or impractical for scanning with RCM as determined by investigator
  6. Patient with co-morbidities such as other skin disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
324 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testIn-vivo imaging

    Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).

06

What researchers measure

Primary outcomes

  1. Sensitivity and Specificity

    Specificity \& Sensitivity of RCM in diagnosing Basal Cell Carcinoma in non-pigmented lesions compared to standard histology

    Time frame: During exam (biopsy results typically available within one week).

Secondary outcomes

  1. intra- & inter-observer agreement for interpreting the RCM images

    A measure of how consistently readers can diagnose from confocal images.

    Time frame: 6 months

07

Study locations

1 site
  • Skin Care Network Barnet Ltd
    London, EN5 4QS, United Kingdom
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Dec 2019, 33 months.

Of 40 observational studies under Carcinoma, Basal Cell, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 75. This study's 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2018
First posted
Apr 26, 2018
StartActual
Mar 15, 2017
Primary completionActual
Dec 28, 2019
CompletionActual
Dec 28, 2019
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03509415
Lead sponsor
Skin Care Network Ltd.
Responsible party
Sponsor
First posted
Apr 26, 2018
Start date
Mar 15, 2017
Primary completion
Dec 28, 2019
Completion
Dec 28, 2019
Last update
Apr 16, 2024

Study contacts

Howard Stevens, MA PhD
principal investigator · Skin Care Network Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion